Skip to content

Kanggan Granular versus Ribavirin Granular for children with influenza -like illness (syndrome of wind-heat invading superficial part): a randomized, double-blind, parallel-group, multi-center clinical trial

Kanggan Granular versus Ribavirin Granular for children with influenza -like illness (syndrome of wind-heat invading superficial part): a randomized, double-blind, parallel-group, multi-center clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003304
Enrollment
Unknown
Registered
2013-07-02
Start date
2013-07-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

influenza-like illness in children

Interventions

experimental group:Kanggan Granule
control group:Ribavirin Granule

Sponsors

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Children meeting the Western diagnostic criteria of influenza-like illness; 2. Children meeting the criteria of syndrome of wind-heat invading superficial part; 3. Aged 1 to 14 years; 4. With pre-diagnostic 24h maximum axillary temperature<=38.5 degree; 5. Disease course <=24 hours; 6. Parents or guardians signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Blood WBC> 10*10^9/L, or the percentage of neutrophilic granulocyte>the upper limit of normal; 2. Having taken other drugs to treat the studied disease before 24 hours prior to this treatment; 3. Patients with severe malnutrition, rickets as well as combined severe primary diseases of heart, brain, liver, kidney and hematopoietic systems etc; 4. Liver function AST, ALT> 1.5N (N is upper limit of normal); renal function (Cr)>the upper limit of normal; 5. Allergic patients (two or more kinds of food or drug allergies) or those who are allergic to the test drug; 6. Patients not suitable for inclusion judged by researchers or influencing participation or completion of the study.

Design outcomes

Primary

MeasureTime frame
fever clearance time;clinical recovery time;

Secondary

MeasureTime frame
AUC of main symptoms (fever, headache, nasal congestion, runny nose, sore throat);effect of TCM syndrom;

Countries

China

Contacts

Public ContactSiyuan Hu
husiyuan1963@sina.com+86 022 27432275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026